Background Artificial Intelligence (AI) is increasingly integrated into oncology, offering opportunities to improve diagnostics, treatment planning, and operational efficiency. However, patient perspectives on AI, especially regarding data protection and ethical implications, remain underexplored. Objective The objective of this study is to investigate cancer patients' attitudes toward the use of Artificial Intelligence (AI) in healthcare, focusing on their awareness of data protection, perceived risks and benefits, and the conditions under which AI is considered acceptable. Additionally, the study aims to examine how demographic and educational factors influence patients' views within the context of an Italian comprehensive cancer center. Methods A cross-sectional survey was conducted with 117 cancer patients who completed a 28-item online questionnaire. The survey evaluated levels of AI knowledge, perceptions of data privacy, concerns about AI in medical contexts, and willingness to share health data for research. Results Most participants demonstrated moderate awareness of AI (70.1%) and its medical applications (85.5%), with higher familiarity observed among younger and more educated individuals. While data protection understanding varied, 76.9% were willing to share personal health data for research aimed at improving cancer care. Concerns included reduced physician autonomy (52.1%) and diminished physician-patient interaction (63.3%). However, 82.9% of respondents found AI acceptable when clinical decisions remained under physician control. AI was most favorably viewed for administrative support and care process optimization. Conclusion Cancer patients generally view AI in healthcare positively, especially when it maintains physician oversight and safeguards data privacy. To ensure equitable and informed adoption, targeted educational initiatives and transparent communication strategies should address generational, educational, and digital literacy differences.

Background/Objectives: Management of cancer treatment-induced bone loss (CTIBL) is essential for preserving quality of life among breast cancer (BC) patients receiving endocrine therapy. However, bone-modifying agents (BMAs) remain underused and delayed. In 2014, IRST launched the first bone health outpatient service in Romagna (the eastern area of the Emilia-Romagna region). A multi-centre, retrospective observational study with propensity score matching (PSM) was conducted to evaluate the impact of the IRST organisational model on bone health. Methods: The PSM matched the Emilia-Romagna patients who underwent BC surgery between 2014 and 2022 and were in follow-up in the Romagna area. Patients were grouped as follows: (1) IRST and (2) other Romagna hospitals (without bone health service, i.e., the control group). The matching was based on age, in situ/invasive cancer, and type of early-stage treatment (hormone treatment vs. chemotherapy). Logistic regression and Cox proportional-hazard models assessed factors associated with bone care treatment initiation and timings, respectively. Results: After PSM, we matched 3112 of the 8021 eligible patients into the two cohorts. IRST patients were 39% more likely to receive BMAs (OR: 1.393; 95% CI: 1.236–1.571) and initiated treatment approximately 12 months earlier. We observed that patients with invasive tumours were 77% more likely to initiate bone therapy than those with in situ tumours (OR: 1.766; 95% CI: 1.237–2.585). The early initiation of bone health therapy was influenced by age (p < 0.001) and neoadjuvant chemotherapy treatment (p < 0.001). Conclusions: The IRST model demonstrates responsiveness to bone health needs in BC patients and may be implemented elsewhere to support integrated CTIBL care.